These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 21215224)

  • 1. [Safety and efficacy of intraoperative defibrillation threshold measured by defibrillation safety margin in 52 patients with implantable cardioverter defibrillator].
    Zhang Y; Yuan KD; Tang BP; Ma YT; Zhang YY; Wang J; Li JX; Zhang JH; Xu GJ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Nov; 38(11):975-8. PubMed ID: 21215224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraoperative defibrillation threshold testing during implantable cardioverter-defibrillator insertion: do we really need it?
    Calvi V; Dugo D; Capodanno D; Arancio R; Di Grazia A; Liotta C; Puzzangara E; Ragusa A; Arestia A; Tamburino C
    Am Heart J; 2010 Jan; 159(1):98-102. PubMed ID: 20102873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Low energy cardioversion with the implantable cardioversion defibrillator devices for treatment of ventricular tachycardia and ventricular fibrillation].
    Siebels J; Schneider MA; Kuck KH
    Z Kardiol; 1993 Nov; 82(11):683-91. PubMed ID: 8291289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraoperative testing of the implantable cardioverter-defibrillator: how much is enough?
    Pires LA; Johnson KM
    J Cardiovasc Electrophysiol; 2006 Feb; 17(2):140-5. PubMed ID: 16533250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transvenous pectoral implantation of single lead implantable cardioverter defibrillator.
    Wang F; Hua W; Chen X
    Chin Med J (Engl); 1999 Jan; 112(1):22-4. PubMed ID: 11593633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Experiences with the new cardioverter-defibrillator Ventak PRxII].
    Pfitzner P; Trappe HJ; Fieguth HG; Kielblock B
    Z Kardiol; 1995 Apr; 84(4):275-83. PubMed ID: 7785299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
    Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
    J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Is ICD-programming for double intraoperative defibrillation threshold energy safe and effective during long-time follow-up? Results of a prospective randomized multicenter study (Low-Energy Endotak Trial--LEET)].
    Himmrich E; Liebrich A; Michel U; Neuzner J; Pitschner H; Heisel A; Vester E; Ganschov U; Jung J
    Z Kardiol; 1999 Feb; 88(2):103-12. PubMed ID: 10209831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of induction method on defibrillation threshold and ventricular fibrillation cycle length.
    Zima E; Gergely M; Soós P; Gellér LA; Nemes A; Acsády G; Merkely B
    J Cardiovasc Electrophysiol; 2006 Apr; 17(4):377-81. PubMed ID: 16643358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of patients with relatively high effective defibrillation threshold during cardioverter defibrillator implantation with endocardial leads.
    Rosenheck S; Sharon Z; Weiss A
    Cardiology; 2009; 112(2):107-13. PubMed ID: 18583908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dilemma of ICD implant testing.
    Swerdlow CD; Russo AM; Degroot PJ
    Pacing Clin Electrophysiol; 2007 May; 30(5):675-700. PubMed ID: 17461879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraoperative defibrillation threshold testing and postoperative long-term efficacy of cardioverter-defibrillator implantation.
    Gan T; Cao X; Yu Z; Tang B; Li J; Xu G; Zhou X; Zhang Y; Li Y; Zhang J
    Exp Ther Med; 2013 Jan; 5(1):323-327. PubMed ID: 23251292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of successful defibrillation threshold test during CRT-D implantation.
    Przybylski A; Oreziak A; Lewandowski Z; Hasiec A; Orczykowski M; Walczak F
    Kardiol Pol; 2010 May; 68(5):512-8. PubMed ID: 20491010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implantable cardioverter defibrillator with and without defibrillation threshold testing.
    Codner P; Nevzorov R; Kusniec J; Haim M; Zabarski R; Strasberg B
    Isr Med Assoc J; 2012 Jun; 14(6):343-6. PubMed ID: 22891393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter experience with a pectoral unipolar implantable cardioverter-defibrillator. Active Can Investigators.
    Bardy GH; Yee R; Jung W
    J Am Coll Cardiol; 1996 Aug; 28(2):400-10. PubMed ID: 8800117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of shock polarity reversal on defibrillation threshold in an implantable cardioverter-defibrillator.
    Zienciuk A; Lubiński A; Królak T; Lewicka-Nowak E; Kempa M; Pazdyga A; Raczak G
    Kardiol Pol; 2007 May; 65(5):495-500; discussion 501-2. PubMed ID: 17577846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of defibrillation efficacy using implantable cardioverter-defibrillator with single- or dual-coil defibrillation leads and active can.
    Lubiński A; Lewicka-Nowak E; Zienciuk A; Królak T; Kempa M; Pazdyga A; Raczak G; Swiatecka G
    Kardiol Pol; 2005 Sep; 63(3):234-41; discussion 242-3. PubMed ID: 16180177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upper limit of vulnerability is a good estimator of shock strength associated with 90% probability of successful defibrillation in humans with transvenous implantable cardioverter-defibrillators.
    Swerdlow CD; Ahern T; Kass RM; Davie S; Mandel WJ; Chen PS
    J Am Coll Cardiol; 1996 Apr; 27(5):1112-8. PubMed ID: 8609329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-tailored implantable cardioverter defibrillator testing using the upper limit of vulnerability: the TULIP protocol.
    Lemke B; Lawo T; Zarse M; Lubinski A; Kreutzer U; Mueller J; Schuchert A; Mitzenheim S; Danilovic D; Deneke T;
    Europace; 2008 Aug; 10(8):907-13. PubMed ID: 18515789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.